Publications

Tap into Gubra’s vast production of publications and posters to get the latest knowledge and insights within our focus areas: diabetes, obesity, NASH and gastrointestinal diseases.

Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative

Liver International [online ahead of print]

Stokman G, van den Hoek AM, Thorbek DD, Pieterman EJ, Veidal SS, Basta B, Iruarrizaga-Lejarreta M, van der Hoorn JW, Verschuren L, Berbée JFP, Rensen PCN, Skjæret T, Alonso C, Feigh M, Kastelein JJP, Friedman SL, Princen HMG, Fraser DA

Publications

Publications

Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative

Low interleukin-22 binding protein is associated with high mortality in alcoholic hepatitis and modulates interleukin-22 receptor expression

Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis

The selective peroxisome proliferator‐activated receptor gamma modulator CHS‐131 improves liver histopathology and metabolism in a mouse model of obesity and nonalcoholic steatohepatitis

Automated image analyses of glomerular hypertrophy in a mouse model of diabetic nephropathy

Whole-brain 3D imaging for quantification of drug targets and treatment effects in mouse models of neurodegenerative diseases

Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis

Activation of adenosine monophosphate-activated protein kinase reduces the onset of diet-induced hepatocellular carcinoma in mice

Rodent models of diabetic kidney disease: human translatability and preclinical validity

Incretin combination therapy for the treatment of non-alcoholic steatohepatitis

Glucagon resistance at the level of amino acid turnover in obese subjects with hepatic steatosis

Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis

Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH

Impact of sex on diabetic nephropathy and the renal transcriptome in UNx db/db C57BLKS mice

Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labelled neuron architecture in the mouse MPTP model of Parkinson's disease

The dorsomedial hypothalamus and nucleus of the solitary tract as key regulators in a rat model of chronic obesity

Global transcriptome analysis of rat hypothalamic arcuate nucleus demonstrates reversal of hypothalamic gliosis following surgically and diet induced weight loss

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice

Mastiha (Pistacia Lentiscus) improves gut microbiota diversity, hepatic steatosis and disease activity in a biopsy-confirmed mouse model of advanced non-alcoholic steatohepatitis and fibrosis

Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source

Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion

Half-Life Extending Modifications of Peptide YY3-36 Direct Receptor-Mediated Internalization

Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery

RhoA in tyrosine hydroxylase neurons regulates food intake and body weight via altered sensitivity to peripheral hormones

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH

The preprohormone expression profile of enteroendocrine cells following Roux-en-Y gastric bypass in rats

Hepatic molecular characteristics of patients with varying degrees of nonalcoholic steatohepatitis compared to healthy normal weight individuals

Experimental non-alcoholic steatohepatitis in Göttingen Minipigs: consequences of high fat-fructose-cholesterol diet and diabetes

Animal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis – clinical translatability and applicability in preclinical drug development

The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach

Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects

Pancreatic β-Cell Rest Replenishes Insulin Secretory Capacity and Attenuates Diabetes in an Extreme Model of Obese Type 2 Diabetes

Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice

Molecular characterization of microvesicular and macrovesicular steatosis shows widespread differences in metabolic pathways

Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis

Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice

Chemical Strategies for Half-life Extension of Biopharmaceuticals: Lipidation and its Alternatives

Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylins do not play a significant role in body weight regulation and glycemic control

INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafbranor in diet-induced obese mouse models of biopsy-confrmed nonalcoholic steatohepatitis

Application of the Physical Disector Principle for Quantification of Dopaminergic Neuronal Loss in a Rat 6-Hydroxydopamine Nigral Lesion Model of Parkinson’s Disease

GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice

In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetes

Mouse models of nonalcoholic steatohepatitis in preclinical drug development

Enteroendocrine K and L cells in healthy and type 2 diabetic individuals

Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues

A hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist

Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia

Neurturin and a GLP-1 analogue act synergistically to alleviate diabetes in Zucker diabetic fatty rats

Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model

The endogenous preproglucagon system is not essential for gut growth homeostasis in mice

Neoglycolipids for prolonging the effects of peptides: Self-assembling glucagon-like peptide 1 analogues with albumin binding properties and potent in vivo efficacy

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates

Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation

Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson’s disease

Effects of Peripheral Neurotensin on Appetite Regulation and Its Role in Gastric Bypass Surgery

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease

Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy

The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice

Rapid gut growth but persistent delay in digestive function in the postnatal period of preterm pigs

The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy

Alterations in hypothalamic gene expression following Roux-en-Y gastric bypass

Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes

A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents

Neuromedin U inhibits food intake partly by inhibiting gastric emptying

The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats

The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease

Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis

Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake

Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca mulatta) Brain

Post-surgical effects of Roux-en-Y gastric bypass on glucose homeostasis, intestinal morphology and L-cells in obese Göttingen minipigs

The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat

The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice

Expression of the fatty acid receptor GPR120 in the gut of diet-induced-obese rats and its role in GLP-1 secretion

The effect of ileal interposition surgery on enteroendocrine cell numbers in the UC Davis type 2 diabetes mellitus rat

Characterisation of age-dependent beta cell dynamics in the male db/db mice